Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation

References

• Mehta-Shah N, Lunning MA, Boruchov AM, et al. A phase I/II trial of the combination of romidepsin and lenalidomide in patients with relapsed/refractory lymphoma and myeloma: activity in T-cell lymphoma. J Clin Oncol. 2015;33:8521.
   Web of Science ®Google Scholar
• Bergmann AK, Schneppenheim S, Seifert M, et al. Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. Genes Chromosomes Cancer. 2014;53:309–316.
   PubMed Web of Science ®Google Scholar
• Dungarwalla M, Matutes E, Dearden CE. Prolymphocytic leukaemia of B- and T-cell subtype: a state-of-the-art paper. Eur J Haematol. 2008;80:469–476.
   PubMed Web of Science ®Google Scholar
• Robak T, Robak P. Current treatment options in prolymphocytic leukemia. Med Sci Monit. 2007;13:RA69–RA80.
   PubMed Web of Science ®Google Scholar
• Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. Jco. 1997;15:2667–2672.
   PubMed Web of Science ®Google Scholar
• Hopfinger G, Busch R, Barbara E, et al. TPLL-1 Protocol of the German CLL Study Group (GCLLSG) - A Prospective Phase II Trial of Fludarabine Phosphate, Mitoxantrone and Cyclophosphamide (FMC) Followed by Alemtuzumab Consolidation in T-PLL. Blood. 2011;110:2039.
   Google Scholar
• Dearden CE, Matutes E, Cazin B, et al. High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H. Blood. 2001;98:1721–1726.
   PubMed Web of Science ®Google Scholar
• Dearden CE, Khot A, Else M, et al. Alemtuzumab therapy in T-cell prolymphocytic leukemia: comparing efficacy in a series treated intravenously and a study piloting the subcutaneous route. Blood. 2011;118:5799.
   PubMed Web of Science ®Google Scholar
• Keating MJ, Cazin B, Coutre S, et al. Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed. Jco. 2002;20:205–213.
   PubMed Web of Science ®Google Scholar
• Krishnan B, Else M, Tjonnfjord GE, et al. Stem cell transplantation after alemtuzumab in T-cell prolymphocytic leukaemia results in longer survival than after alemtuzumab alone: a multicentre retrospective study. Br J Haematol. 2010;149:907–910.
   PubMed Web of Science ®Google Scholar
• Dearden C. How I treat prolymphocytic leukemia. Blood. 2012;120:538.
   PubMed Web of Science ®Google Scholar
• Herling M, Patel KA, Teitell MA, et al. High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. Blood. 2008;111:328.
   PubMed Web of Science ®Google Scholar
• Stengel A, Kern W, Zenger M, et al. Genetic characterization of T-PLL reveals two major biologic subgroups and JAK3 mutations as prognostic marker. Genes Chromosomes Cancer. 2016;55:82–94.
   PubMed Web of Science ®Google Scholar
• Bellanger D, Jacquemin V, Chopin M, et al. Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. Leukemia. 2014;28:417–419.
   PubMed Web of Science ®Google Scholar
• Tirado CA, Starshak P, Delgado P, et al. “T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach”. Exp Hematol Oncol. 2012;1:21.
   PubMedGoogle Scholar
• Durig J, Bug S, Klein-Hitpass L, et al. Combined single nucleotide polymorphism-based genomic mapping and global gene expression profiling identifies novel chromosomal imbalances, mechanisms and candidate genes important in the pathogenesis of T-cell prolymphocytic leukemia with inv(14)(q11q32). Leukemia. 2007;21:2153–2163.
   PubMed Web of Science ®Google Scholar
• Kiel MJ, Velusamy T, Rolland D, et al. Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014;124:1460–1472.
   PubMed Web of Science ®Google Scholar
• Springuel L, Renauld JC, Knoops L. JAK kinase targeting in hematologic malignancies: a sinuous pathway from identification of genetic alterations towards clinical indications. Haematologica. 2015;100:1240–1253.
   PubMed Web of Science ®Google Scholar
• Liongue C, Ward AC. Evolution of the JAK-STAT pathway. Jakstat. 2013;2:e22756.
   PubMedGoogle Scholar
• Roskoski R, Jr. Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases. Pharmacol Res. 2016;111:784–803.
   PubMed Web of Science ®Google Scholar
• Akada H, Akada S, Hutchison RE, et al. Critical role of Jak2 in the maintenance and function of adult hematopoietic stem cells. Stem Cells. 2014;32:1878–1889.
   PubMed Web of Science ®Google Scholar
• Haan C, Rolvering C, Raulf F, et al. Jak1 has a dominant role over Jak3 in signal transduction through gammac-containing cytokine receptors. Chem Biol. 2011;18:314–323.
   PubMed Web of Science ®Google Scholar
• Yamashita Y, Yuan J, Suetake I, et al. Array-based genomic resequencing of human leukemia. Oncogene. 2010;29:3723–3731.
   PubMed Web of Science ®Google Scholar
• Degryse S, de Bock CE, Cox L, et al. JAK3 mutants transform hematopoietic cells through JAK1 activation, causing T-cell acute lymphoblastic leukemia in a mouse model. Blood. 2014;124:3092–3100.
   PubMed Web of Science ®Google Scholar
• Springuel L, Hornakova T, Losdyck E, et al. Cooperating JAK1 and JAK3 mutants increase resistance to JAK inhibitors. Blood. 2014;124:3924–3931.
   PubMed Web of Science ®Google Scholar
• Greenplate A, Wang K, Tripathi RM, et al. Genomic profiling of T-cell neoplasms reveals frequent JAK1 and JAK3 mutations with clonal evasion from targeted therapies. JCO Precis Oncol. 2018. DOI:10.1200/PO.17.00019
   PubMed Web of Science ®Google Scholar
• Gavegnano C, Detorio M, Montero C, et al. Ruxolitinib and tofacitinib are potent and selective inhibitors of HIV-1 replication and virus reactivation in vitro. Antimicrob Agents Chemother. 2014;58:1977–1986.
   PubMed Web of Science ®Google Scholar